Patents by Inventor Joachim Struck

Joachim Struck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10254289
    Abstract: The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: April 9, 2019
    Assignee: B.R.A.H.M.S. GmbH
    Inventors: Andreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck, Leong L. Ng
  • Publication number: 20190041408
    Abstract: The present invention relates to an in vitro method for the detection of Procalcitonin or a fragment thereof of at least 20 amino acid residues in length in a biological sample derived from a bodily fluid obtained from a subject, comprising the steps of: (i) contacting said sample with at least two antibodies or functional fragments thereof directed against different epitopes within Procalcitonin, and (ii) qualitatively or quantitatively detecting binding of said at least two antibodies to Procalcitonin or said fragment thereof, wherein binding indicates the presence or concentration of Procalcitonin or said fragment in said sample, wherein at least one antibody or functional fragment thereof is directed against an epitope comprised in the sequence spanning amino acid residues 2 to 52 of Procalcitonin. The invention also pertains to antibodies directed against an N-terminal epitope of Procalcitonin and kits comprising antibodies directed against PCT.
    Type: Application
    Filed: August 10, 2018
    Publication date: February 7, 2019
    Applicants: B.R.A.H.M.S GMBH
    Inventor: Joachim STRUCK
  • Publication number: 20180252732
    Abstract: Method of obtaining and/or verifying a binder to prepro-Vasopressin (SEQ ID NO. 1) or fragments thereof of at least 6 amino acids in length, including Copeptin (SEQ ID NO. 2), comprising at least one of the steps of: a) generating the binder using a developer comprising an amino acid sequence of at least 6 amino acids in length contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); b) determining whether the binder is capable of binding to an amino acid sequence of at least 4 amino acids in length contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO. 1); c) selecting and optionally isolating the binder from a plurality of binders which is capable of binding to an amino acid sequence contained in an amino acid sequence corresponding to the C-terminal part but lacking amino acid 164 of prepro-Vasopressin (SEQ ID NO.
    Type: Application
    Filed: May 1, 2018
    Publication date: September 6, 2018
    Inventor: Joachim Struck
  • Patent number: 10048280
    Abstract: The present invention relates to an in vitro method for the detection of Procalcitonin or a fragment thereof of at least 20 amino acid residues in length in a biological sample derived from a bodily fluid obtained from a subject, comprising the steps of: (i) contacting said sample with at least two antibodies or functional fragments thereof directed against different epitopes within Procalcitonin, and (ii) qualitatively or quantitatively detecting binding of said at least two antibodies to Procalcitonin or said fragment thereof, wherein binding indicates the presence or concentration of Procalcitonin or said fragment in said sample, wherein at least one antibody or functional fragment thereof is directed against an epitope comprised in the sequence spanning amino acid residues 2 to 52 of Procalcitonin. The invention also pertains to antibodies directed against an N-terminal epitope of Procalcitonin and kits comprising antibodies directed against PCT.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: August 14, 2018
    Assignee: B.R.A.H.M.S GMBH
    Inventor: Joachim Struck
  • Patent number: 10024872
    Abstract: The present invention relates to an immunoassay method for the detection of augurin or a precursor or fragment thereof comprising contacting a sample suspected of comprising augurin or a precursor or fragment thereof with a first and second antibody specific for augurin or a precursor or fragment thereof, wherein said first and second antibodies or antigen-binding fragments or derivatives thereof are specific for epitopes comprised in the sequence spanning amino acids 71 to 107 of pre-augurin according to SEQ ID NO:1.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: July 17, 2018
    Assignee: B.R.A.H.M.S GmbH
    Inventors: Joachim Struck, Tim Ziera
  • Publication number: 20180143190
    Abstract: Method for the determination of adrenomedullin immunoreactivity in biological fluids for diagnostic purposes, in particular in sepsis, cardiac and cancer diagnosis, in which the midregional partial peptide (mid-proAM; SEQ ID NO:3) of proadrenomedullin, which comprises the amino acids (45-92) of the complete preproadrenomedullin (pre-proAM; SEQ ID NO:1), is measured in particular by means of an immunoassay which operates with at least one labelled antibody which specifically recognizes a sequence of mid-proAM.
    Type: Application
    Filed: January 12, 2018
    Publication date: May 24, 2018
    Applicant: B.R.A.H.M.S GmbH
    Inventors: Andreas BERGMANN, Joachim STRUCK
  • Patent number: 9952229
    Abstract: Subject of the present invention are assays and in vitro methods for the prediction of the risk of a subject for contracting metabolic syndrome and/or diabetes mellitus and for diagnosing metabolic syndrome, comprising determining the level of arginine vasopressin pro-hormone or fragments thereof in a sample of a subject.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: April 24, 2018
    Assignees: B.R.A.H.M.S. GmbH, The General Hospital Corporation
    Inventors: Joachim Struck, Andreas Bergmann, Olle Melander, Christopher Newton-Cheh, Thomas Wang
  • Publication number: 20180052179
    Abstract: A diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic, as well as a kit for performing the method and methods of treatment based thereon.
    Type: Application
    Filed: November 6, 2017
    Publication date: February 22, 2018
    Applicant: B.R.A.H.M.S GmbH
    Inventors: Andreas BERGMANN, Joachim STRUCK
  • Patent number: 9885709
    Abstract: Method for the determination of adrenomedullin immunoreactivity in biological fluids for diagnostic purposes, in particular in sepsis, cardiac and cancer diagnosis, in which the midregional partial peptide (mid-proAM; SEQ ID NO:3) of proadrenomedullin, which comprises the amino acids (45-92) of the complete preproadrenomedullin (pre-proAM; SEQ ID NO:1), is measured in particular by means of an immunoassay which operates with at least one labelled antibody which specifically recognizes a sequence of mid-proAM.
    Type: Grant
    Filed: January 29, 2004
    Date of Patent: February 6, 2018
    Assignee: B.R.A.H.M.S. GMBH
    Inventors: Andreas Bergmann, Joachim Struck
  • Publication number: 20170370949
    Abstract: The present invention relates to the determination of the level of marker peptides in a sample derived from a bodily fluid of a subject presenting with non-specific complaints.
    Type: Application
    Filed: September 11, 2017
    Publication date: December 28, 2017
    Applicant: B.R.A.H.M.S GMBH
    Inventors: Joachim STRUCK, Christian NICKEL, Roland BINGISSER, Sven GIERSDORF, Oliver HARTMANN
  • Publication number: 20170370940
    Abstract: The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).
    Type: Application
    Filed: September 1, 2017
    Publication date: December 28, 2017
    Applicant: B.R.A.H.M.S. GmbH
    Inventors: Joachim STRUCK, John GF CLELAND
  • Patent number: 9829494
    Abstract: The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used as for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: November 28, 2017
    Assignee: ADRENOMED AG
    Inventors: Andreas Bergmann, Joachim Struck, Nils G. Morgenthaler
  • Patent number: 9810699
    Abstract: A diagnostic method for the identification of a subject suffering from a primary non-infectious disease having an increased risk of an adverse outcome potentially being induced by the administration of an antibiotic to said subject comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof or a precursor or fragment thereof having a length of at least 12 amino acid residues in a sample of a bodily fluid from said subject and the correlation of the determined level to a potential risk induced by the administration of an antibiotic, as well as a kit for performing the method and methods of treatment based thereon.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 7, 2017
    Assignee: B.R.A.H.M.S GMBH
    Inventors: Andreas Bergmann, Joachim Struck
  • Patent number: 9753039
    Abstract: The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 5, 2017
    Assignee: B.R.A.H.M.S GmbH
    Inventors: Joachim Struck, John GF Cleland
  • Publication number: 20170242037
    Abstract: Disclosed herein is the use of copeptin as a diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases.
    Type: Application
    Filed: February 27, 2017
    Publication date: August 24, 2017
    Applicant: B.R.A.H.M.S GMBH
    Inventors: Andreas BERGMANN, Joachim STRUCK
  • Patent number: 9726675
    Abstract: The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No. 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: August 8, 2017
    Assignee: B.R.A.H.M.S. GMBH
    Inventors: Andreas Bergmann, Joachim Struck
  • Patent number: 9664689
    Abstract: The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of intact procalcitonin 1-116, or procalcitonin partial peptides derived therefrom that retain amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116. The method uses antibodies that selectively bind an epitope comprising amino acids 1 and 2 of procalcitonin 1-116 (SEQ ID NO: 1) and can distinguish between intact procalcitonin 1-116 and for example, procalcitonin 3-116.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: May 30, 2017
    Assignee: B.R.A.H.M.S GMBH
    Inventors: Andreas Bergmann, Joachim Struck
  • Publication number: 20170131297
    Abstract: The present invention relates to an in vitro method for the detection of Procalcitonin or a fragment thereof of at least 20 amino acid residues in length in a biological sample derived from a bodily fluid obtained from a subject, comprising the steps of: (i) contacting said sample with at least two antibodies or functional fragments thereof directed against different epitopes within Procalcitonin, and (ii) qualitatively or quantitatively detecting binding of said at least two antibodies to Procalcitonin or said fragment thereof, wherein binding indicates the presence or concentration of Procalcitonin or said fragment in said sample, wherein at least one antibody or functional fragment thereof is directed against an epitope comprised in the sequence spanning amino acid residues 2 to 52 of Procalcitonin. The invention also pertains to antibodies directed against an N-terminal epitope of Procalcitonin and kits comprising antibodies directed against PCT.
    Type: Application
    Filed: January 23, 2017
    Publication date: May 11, 2017
    Applicant: B.R.A.H.M.S GMBH
    Inventor: Joachim STRUCK
  • Publication number: 20170059583
    Abstract: The invention relates to a method for diagnosing and/or stratifying the risk of infections or chronic diseases of the respiratory tract and lungs, particularly lower respiratory tract infections and chronic obstructive pulmonary disease. In said method, provasopressin (proAVP) or fragments or partial peptides thereof, especially copeptin or neurophysin II, is/are determined. The invention further relates to suitable biomarker combinations for in-vitro diagnosis.
    Type: Application
    Filed: June 13, 2016
    Publication date: March 2, 2017
    Applicant: BRAHMS GmbH
    Inventors: Andreas BERGMANN, Nils MORGENTHALER, Jana PAPASSOTIRIOU, Joachim STRUCK, Beat Muller
  • Patent number: 9541549
    Abstract: Method for the determination of adrenomedullin immunoreactivity in biological fluids for diagnostic purposes, in particular in sepsis, cardiac and cancer diagnosis, in which the midregional partial peptide (mid-proAM; SEQ ID NO:3) of proadrenomedullin, which comprises the amino acids (45-92) of the complete preproadrenomedullin (pre-proAM; SEQ ID NO:1), is measured in particular by means of an immunoassay which operates with at least one labelled antibody which specifically recognizes a sequence of mid-proAM.
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: January 10, 2017
    Assignee: B.R.A.H.M.S. GMBH
    Inventors: Andreas Bergmann, Joachim Struck